» Articles » PMID: 34150747

Macrophages Derived From Human Induced Pluripotent Stem Cells: The Diversity of Protocols, Future Prospects, and Outstanding Questions

Overview
Specialty Cell Biology
Date 2021 Jun 21
PMID 34150747
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages (Mφ) derived from induced pluripotent stem cells (iMphs) represent a novel and promising model for studying human Mφ function and differentiation and developing new therapeutic strategies based on or oriented at Mφs. iMphs have several advantages over the traditionally used human Mφ models, such as immortalized cell lines and monocyte-derived Mφs. The advantages include the possibility of obtaining genetically identical and editable cells in a potentially scalable way. Various applications of iMphs are being developed, and their number is rapidly growing. However, the protocols of iMph differentiation that are currently used vary substantially, which may lead to differences in iMph differentiation trajectories and properties. Standardization of the protocols and identification of minimum required conditions that would allow obtaining iMphs in a large-scale, inexpensive, and clinically suitable mode are needed for future iMph applications. As a first step in this direction, the current review discusses the fundamental basis for the generation of human iMphs, performs a detailed analysis of the generalities and the differences between iMph differentiation protocols currently employed, and discusses the prospects of iMph applications.

Citing Articles

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.


The Generation of Genetically Engineered Human Induced Pluripotent Stem Cells Overexpressing IFN-β for Future Experimental and Clinically Oriented Studies.

Sheveleva O, Protasova E, Grigoreva E, Butorina N, Kuziaeva V, Antonov D Int J Mol Sci. 2024; 25(22).

PMID: 39596521 PMC: 11595023. DOI: 10.3390/ijms252212456.


Synergy between pluripotent stem cell-derived macrophages and self-renewing macrophages: Envisioning a promising avenue for the modelling and cell therapy of infectious diseases.

Peng D, Li M, Yu Z, Yan T, Yao M, Li S Cell Prolif. 2024; 58(2):e13770.

PMID: 39537185 PMC: 11839195. DOI: 10.1111/cpr.13770.


Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease.

Tiwari S, Wong W, Moreira M, Pasqualini C, Ginhoux F Nat Rev Immunol. 2024; 25(2):108-124.

PMID: 39333753 DOI: 10.1038/s41577-024-01081-x.


How can we use stem cell-derived cardiomyocytes to understand the involvement of energetic metabolism in alterations of cardiac function?.

Rebs S, Streckfuss-Bomeke K Front Mol Med. 2024; 3:1222986.

PMID: 39086669 PMC: 11285589. DOI: 10.3389/fmmed.2023.1222986.


References
1.
Zhang P, Li J, Tan Z, Wang C, Liu T, Chen L . Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells. Blood. 2007; 111(4):1933-41. DOI: 10.1182/blood-2007-02-074120. View

2.
Lacaud G, Kouskoff V . Hemangioblast, hemogenic endothelium, and primitive versus definitive hematopoiesis. Exp Hematol. 2017; 49:19-24. DOI: 10.1016/j.exphem.2016.12.009. View

3.
Ginhoux F, Guilliams M . Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016; 44(3):439-449. DOI: 10.1016/j.immuni.2016.02.024. View

4.
Zhang X, Goncalves R, Mosser D . The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008; Chapter 14:14.1.1-14.1.14. PMC: 2834554. DOI: 10.1002/0471142735.im1401s83. View

5.
Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View